LuGENE®

About AMPEL BioSolutions

AMPEL BioSolutions is a private, commercial-stage biotech leveraging a proprietary AI-driven genomic platform to bring precision medicine to complex autoimmune diseases. The company has launched its first laboratory-developed test (LDT), LuGENE® for lupus, and has a pipeline of planned tests in dermatology and wellness. AMPEL's competitive edge stems from its disease-agnostic platform and what it claims is the world's largest curated database of autoimmune patient gene expression profiles, which fuels its machine learning models. The company is positioned at the intersection of diagnostics, AI, and immunology, aiming to reduce uncertainty in clinical decision-making for dynamic chronic conditions.

Therapeutic Areas